Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Malaga Cove Capital LLC

Malaga Cove Capital LLC reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 50.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,901 shares of the medical research company’s stock after selling 1,955 shares during the quarter. Malaga Cove Capital LLC’s holdings in Charles River Laboratories International were worth $374,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the business. Oregon Public Employees Retirement Fund grew its stake in Charles River Laboratories International by 1.0% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock worth $914,000 after buying an additional 45 shares during the last quarter. American Trust boosted its holdings in Charles River Laboratories International by 5.9% in the second quarter. American Trust now owns 976 shares of the medical research company’s stock worth $202,000 after acquiring an additional 54 shares in the last quarter. Tortoise Investment Management LLC grew its stake in shares of Charles River Laboratories International by 77.0% during the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after acquiring an additional 57 shares during the last quarter. OLD National Bancorp IN increased its holdings in shares of Charles River Laboratories International by 3.1% during the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock valued at $392,000 after acquiring an additional 59 shares in the last quarter. Finally, Mitchell & Pahl Private Wealth LLC raised its position in shares of Charles River Laboratories International by 2.0% in the 2nd quarter. Mitchell & Pahl Private Wealth LLC now owns 3,154 shares of the medical research company’s stock valued at $652,000 after purchasing an additional 62 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CRL has been the topic of several research analyst reports. Barclays dropped their target price on shares of Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. Baird R W downgraded Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th. UBS Group lowered their price target on Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. StockNews.com upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Wednesday, October 16th. Finally, JPMorgan Chase & Co. cut Charles River Laboratories International from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $270.00 to $205.00 in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $209.00.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $214.25 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.58 and a quick ratio of 1.21. The stock has a market capitalization of $11.06 billion, a price-to-earnings ratio of 25.66, a PEG ratio of 6.20 and a beta of 1.38. The firm’s 50 day simple moving average is $193.34 and its 200-day simple moving average is $208.60. Charles River Laboratories International, Inc. has a 12 month low of $166.87 and a 12 month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.39 by $0.41. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. Analysts expect that Charles River Laboratories International, Inc. will post 10.01 EPS for the current year.

Charles River Laboratories International declared that its board has authorized a share repurchase program on Wednesday, August 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).